Table 2: BLLs in the two groups of the studied cases at the time of diagnosis and changes in its levels overtime of treatment.
G I (n = 50) | G II (n = 50) | P- value | ||
BLL 0 | 37.84 ± 10.14 | 39.33 ± 8.28 | P 0-1 | 0.42 |
BLL 1 | 26.59 ± 8.45 | 40.49 ± 8.27 | P 0-2 | 0.00 |
BLL 2 | 18.81 ± 7.90 | 40.01 ± 7.46 | P 1-2 | 0.00 |
Paired difference0-1 & (P0-1) |
11.25 ± 2.97 0.00 |
-1.16 ± 0.80 0.00 |
||
Paired difference0-2 & (P0-2) |
19.10 ± 4.15 0.00 |
1.75 ± 1.14 0.00 |
||
Paired difference1-2 & (P1-2) |
18.81 ± 7.90 0.00 |
40.01 ± 7.46 0.00 |
G I: group I (received NAC supplementation); G II: group IV (received none of the supplements); P-value is significant at ≤ 0.05; BLL0: Blood lead level at the time of diagnosis of preeclampsia; BLL1: BLL at first follow up; after 4 weeks of treatment; BLL2: BLL at the second follow up; after 6 weeks of treatment.